Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
C-Rad AB Class B ( ($SE:CRAD.B) ) has provided an announcement.
C-RAD reported a mixed first quarter of 2026, with order intake rising 19 percent to MSEK 115 while revenue fell 12 percent to MSEK 105 and organic growth slipped 4 percent. Profitability improved, as EBIT increased to MSEK 12 with a 12 percent margin, or MSEK 22 and a 21 percent margin excluding restructuring one-offs, while earnings after tax recovered sharply, though operating cash flow turned negative due mainly to tax payments.
New CEO-led management launched an integrated transformation and growth program built around five pillars aimed at driving growth, profitability, cash flow, scalability, and innovation to reach targets of at least 10 percent organic growth and a 25 percent EBIT margin. As part of this shift, C-RAD is restructuring about 13 percent of its global workforce and reallocating resources toward commercial growth, key markets, innovation, software, and recurring revenues, signaling a push to strengthen its competitive position and build a more scalable oncology platform.
More about C-Rad AB Class B
C-RAD AB is a medical technology company focused on advanced solutions for radiation therapy in oncology. The group develops and sells products and services that support precise patient positioning, monitoring, and workflow optimization in cancer treatment, with a growing emphasis on software, clinical workflows, and recurring revenue models in prioritized markets such as the U.S.
Average Trading Volume: 24,117
Technical Sentiment Signal: Sell
Current Market Cap: SEK871.2M
For a thorough assessment of CRAD.B stock, go to TipRanks’ Stock Analysis page.